Status:
RECRUITING
Clinical Study on the Treatment of Malignant Brain Glioma by QH104 Cell Injection
Lead Sponsor:
Dushu Lake Hospital Affiliated to Soochow University
Conditions:
Brain Gliomas
High-Grade Gliomas
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
PHASE2
Brief Summary
B7-H3 is expressed at low levels in normal tissues but overexpressed in various tumor tissues. The ubiquitous expression of B7-H3 in tumors of different grades is a key feature for brain gliomas. The ...
Eligibility Criteria
Inclusion
- 1)Age 18-70 years old (both ends included), both male and female;
- 2)At least one evaluable lesion, with previous biopsy or histopathological confirmation of high-grade glioma (WHO grade 3-4), and after comprehensive treatment, imaging examination indicates continued progression or recurrence;
- 3\) The pathological tissues removed by surgery can be used for immunohistochemical detection of target proteins (paraffin sections should be within half a year), and the expression of B7-H3 is positive;
- 4\) KPS ≥ 60 points;
- 5)Expected survival \> 3 months;
- 6)Substantially normal bone marrow reserve function and normal liver and renal function (laboratory tests need to be fulfilled before receiving QH104 Cell Injection for the first time):White blood cell count (WBC) ≥ 3 x 10\^9/L;Lymphocyte count (LY) ≥ 0.8 x 10\^9/L;Hemoglobin (Hb) ≥ 90g/L;Platelet (PLT) ≥80×10\^9/L;Albumin transaminase (ALT) \& albumin transaminase (AST) \<1.5×ULN;Serum creatinine (Cr) \<1.5 x ULN;Total bilirubin \< 1.5 x ULN;PT \& PTT ≤ 1.25 x ULN.
- 7)No obvious hereditary diseases;
- 8)Normal cardiac function with cardiac ejection index \>55%;
- 9)No bleeding and coagulation disorders;
- 10)Women of childbearing age (15-49 years old) must have had a pregnancy test with a negative result within 7 days prior to the start of treatment, and subjects are willing to use contraception during the clinical trial and for 3 months after the last cell infusion;
- 11\) Sign the informed consent form.
Exclusion
- 1)Pregnant and lactating women;
- 2)Those with organ failure:Heart: Class III and IV;Liver: up to grade C of the Child-Turcotte Liver -Function Classification;Kidney: chronic kidney disease stage 4 or above; renal insufficiency stage III or above;Lungs: symptoms of severe respiratory failure with involvement of other organs;Brain: central nervous system abnormalities or impaired consciousness;
- 3)patients with combined second tumors;
- 4)patients with active hepatitis B or C virus, HIV infection, or other untreated active infection;
- 5)any severe, uncontrolled systemic autoimmune disease or any unstable systemic disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, ulcerative colitis, Crohn's disease, and temporal arteritis;
- 6)Current systemic use of steroid cell (except for recent or current use of inhaled steroids) substances;
- 7\) have a chronic disease requiring immunologic or hormonal therapy;
- 8\) have an allergy to immunotherapy and related cells;
- 9\) 10)Patients with a history of organ transplantation or who are awaiting organ transplantation;
- 10)Participation in other clinical trials within the previous 30 days;
- 11)Those who are not suitable for clinical trials for other reasons in the opinion of the investigator.
Key Trial Info
Start Date :
June 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT06018363
Start Date
June 1 2023
End Date
December 31 2027
Last Update
August 19 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dushu Lake Hospital Affiliated to Soochow University
Suzhou, Jiangsu, China, 215125